CardioDx, Inc. Release: The Corus® CAD Gene Expression Test Can Help Commercial Health Plans Reduce Costs By Improving The Accuracy Of The Diagnostic Workup In Patients With Suspected Obstructive Coronary Artery Disease

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PALO ALTO, CA--(Marketwired - Feb 26, 2014) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced a new publication on the economic utility of Corus® CAD for the assessment of patients with symptoms suggestive of obstructive coronary artery disease (CAD). The analysis found that by using Corus CAD prior to referral for cardiac imaging, a commercial health plan can realize an estimated 9.4% reduction in costs compared to the usual care, for a projected savings of $0.77 per member per month, or $4.59 million for a health plan covering 500,000 adult lives.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC